Trial
NCT04839965
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Ampio Pharmaceuticals. Inc.
Collaborators
—
Condition
COVID-19
Intervention
Ampion
Why stopped
The AP-017 study was prematurely terminated by the sponsor after an interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-30